DIFFERENTIAL UPTAKE OF IMMUNO-ONCOLOGY (IO) TREATMENTS AMONG DIFFERENT INCOME LEVELS FOR NON-SMALL CELL CANCER PATIENTS IN CHINA

被引：0

作者：

De Richter, P. ^{[1
]}

机构：

[1] Ipsos, Kuala Lumpur 14, Malaysia

来源：

VALUE IN HEALTH | 2020年 / 23卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN246

引用

页码：S66 / S66

页数：1

共 50 条

[21] CHANGES IN MORTALITY RATES WITH THE INTRODUCTION OF IMMUNO-ONCOLOGY THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: A SEER-MEDICARE ANALYSIS
Kim, Y.
Lee, J.
Suh, H. S.
Park, C.
[J]. VALUE IN HEALTH, 2024, 27 (06) : S48 - S48
[22] Immuno-oncology biomarker study in non-small cell lung cancer harboring oncogenic driver alterations: LC-SCRUM-IBIS
Kodani, Masahiro
Yoh, Kiyotaka
Matsumoto, Shingo
Kunimasa, Kei
Nishi, Koichi
Nakagawa, Taku
Sugawara, Shunichi
Kato, Tomohiro
Sakakibara-Konishi, Jun
Tsuta, Koji
Hayashi, Yuichiro
Motoi, Noriko
Ishii, Genichiro
Goto, Koichi
[J]. ANNALS OF ONCOLOGY, 2019, 30 : 113 - 113
[23] Real-world immuno-oncology (IO) therapy treatment patterns and outcomes in patients with anaplastic lymphoma kinase positive (ALK1) non-small cell lung cancer (NSCLC) in the United States
Pan, X.
Lin, M. M.
Yin, Y.
Hou, P.
Baumann, P.
Jahanzeb, M.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[24] Pioneer Study: Precision Immuno-Oncology for Advanced Non-Small Cell Lung Cancer Patients with PD1/L1 ICI Resistance
Barlesi, F.
Perol, D.
Mazieres, J.
Perol, M.
Varoqueaux, N.
Monville, F.
Audigier-Valette, C.
Barre, P.
Domergue, F.
Falchero, L.
Foa, C.
Frikha, A.
Hominal, S.
Le Treut, J.
Zahi, S.
Roumieux, M.
Olive, D.
Vivier, E.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S452
[25] Integration of immuno-oncology (IO) treatments into routine clinical practice for the treatment of patients with advanced or metastatic cancers: Analysis of the England national cancer registry
Mahmoudpour, Hamid
Knott, Craig
Amin, Amerah
Boutmy, Emmanuelle
Verpillat, Patrice
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 121 - 121
[26] Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Harsha Ranganath
Amit L. Jain
Justin R. Smith
Julie Ryder
Amina Chaudry
Emily Miller
Felicia Hare
Poojitha Valasareddy
Robert S. Seitz
David R. Hout
Matthew G. Varga
Brock L. Schweitzer
Tyler J. Nielsen
Janice Mullins
Douglas T. Ross
David R. Gandara
Gregory A. Vidal
[J]. BMC Cancer, 22
[27] Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Ranganath, Harsha
Jain, Amit L.
Smith, Justin R.
Ryder, Julie
Chaudry, Amina
Miller, Emily
Hare, Felicia
Valasareddy, Poojitha
Seitz, Robert S.
Hout, David R.
Varga, Matthew G.
Schweitzer, Brock L.
Nielsen, Tyler J.
Mullins, Janice
Ross, Douglas T.
Gandara, David R.
Vidal, Gregory A.
[J]. BMC CANCER, 2022, 22 (01)
[28] VALUE OF INNOVATION IN ONCOLOGY TREATMENTS FOR PATIENTS IN SWEDEN WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Justo, N.
Nilsson, J.
Korytowsky, B.
Chehab, N.
Stanford, A.
Mcguire, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A167 - A167
[29] Prognostic implication of erector spinae muscles in non-small-cell lung cancer patients treated with immuno-oncology combinatorial chemotherapy
Araki, Taisuke
Kitaguchi, Yoshiaki
Suzuki, Yusuke
Komatsu, Masamichi
Sonehara, Kei
Wada, Yosuke
Tateishi, Kazunari
Hanaoka, Masayuki
[J]. THORACIC CANCER, 2021, 12 (21) : 2857 - 2864
[30] Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
Gutierrez, M. E.
Norden, A. D.
Lane, D. C.
Canavan, B. F.
Nwokeji, E. D.
Xu, Y.
Kaur, S.
Goldberg, S. L.
Noh, L.
Siegartel, L.
Whittington, J.
Tuell, K.
Korytowsky, B.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 436 - 437

← 1 2 3 4 5 →